BioNxt Solutions Inc. (BNXTF) News
Track canonical SquawkNews coverage tagged to BNXTF, BioNxt Solutions Inc.. This hub brings together deduplicated headlines about otc markets otcqb, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 7 indexed stories across 7 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
BioNxt advances sublingual everolimus ODF; large-animal PK study begins
BioNxt is advancing its sublingual everolimus ODF for organ transplant rejection and has initiated a large-animal pharmacokinetic study.
EQUITY | Sep 08, 2026, 07:05 AM UTC
L
BioNxt Solutions closes convertible debenture extension; issues warrants
BioNxt Solutions Inc. announces the closing of an extension of convertible debentures and the issuance of warrants, according to TradeXchange Newsdesk.
MNA | Aug 21, 2026, 10:30 PM UTC
L
BioNxt provides development and IP update across sublingual pipeline
BioNxt (BNXTF) issues a development, intellectual property, and commercial update across its sublingual drug delivery pipeline.
EQUITY | Aug 17, 2026, 10:40 AM UTC
M
BioNxt Updates Sublingual Drug Pipeline
BioNxt provides development update
EQUITY | Aug 04, 2026, 07:05 AM UTC
L
BioNxt Solutions Announces Option Grants
BioNxt Solutions grants options
EQUITY | Jul 31, 2026, 10:26 PM UTC
L
BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway
VANCOUVER, BC / / July 6, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:B
EQUITY | Jul 06, 2026, 07:05 AM UTC
L
BNXT: Closes Private Placement
BioNxt announces closing of non-brokered private placement of units
EQUITY | Jun 23, 2026, 09:20 PM UTC